Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma

Proteomic characterization of human multiple myeloma bone marrow extracellular matrix

(2017) S V Glavey et al.   LEUKEMIA

Therapy for Relapsed Multiple Myeloma

(2017) David Dingli et al.   MAYO CLINIC PROCEEDINGS

The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma

(2017) Yuji Mishima et al.   Cell Reports

Genetic interrogation of circulating multiple myeloma cells at single-cell resolution

(2016) J. G. Lohr et al.   Science Translational Medicine

Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response

(2016) N Nikesitch et al.   Blood Cancer Journal

De novo HAPLN1 expression hallmarks Wnt-induced stem cell and fibrogenic networks leading to aggressive human hepatocellular carcinomas

(2016) Sihem Mebarki et al.   Oncotarget

Microenvironment drug resistance in multiple myeloma: emerging new players

(2016) Lucia Di Marzo et al.   Oncotarget

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

(2015) J Laubach et al.   LEUKEMIA

Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer

(2015) Suniti Misra et al.   Frontiers in Immunology

A critical role for the NFkB pathway in multiple myeloma

(2015)   Oncotarget

Overcoming bortezomib resistance in multiple myeloma

(2014) Megan Y. Murray et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back

(2014) Giada Bianchi et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

(2014) Jens G. Lohr et al.   CANCER CELL

The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF- B Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells

(2014) J. C. Godbersen et al.   CLINICAL CANCER RESEARCH

Matricryptins and matrikines: biologically active fragments of the extracellular matrix

(2014) Sylvie Ricard-Blum et al.   EXPERIMENTAL DERMATOLOGY

Covalent Modification of the NF-κB Essential Modulator (NEMO) by a Chemical Compound Can Regulate Its Ubiquitin Binding Propertiesin Vitro

(2014) Christopher Hooper et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Global cellular response to chemotherapy-induced apoptosis

(2013) Arun P Wiita et al.   eLife

Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells

(2012) Jaehyup Kim et al.   BRITISH JOURNAL OF HAEMATOLOGY

NF- B, the first quarter-century: remarkable progress and outstanding questions

(2012) M. S. Hayden et al.   GENES & DEVELOPMENT

Ubiquitination in signaling to and activation of IKK

(2012) Zhijian J. Chen   IMMUNOLOGICAL REVIEWS

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

Inflammation meets cancer, with NF-κB as the matchmaker

(2011) Yinon Ben-Neriah et al.   NATURE IMMUNOLOGY

The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation

(2011) P. Walter et al.   SCIENCE

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF- B-dependent lymphoma

(2010) M. A. Milhollen et al.   BLOOD

Ubiquitylation and proteasomal degradation of the p21Cip1, p27Kip1and p57Kip2CDK inhibitors

(2010) Zhimin Lu et al.   CELL CYCLE

Non-canonical NF-κB signaling pathway

(2010) Shao-Cong Sun   CELL RESEARCH

Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells

(2010) Stephanie Markovina et al.   Molecular Cancer

Distinct Genetic Alterations in Colorectal Cancer

(2010) Hassan Ashktorab et al.   PLoS One

Oncogenic Activation of NF- B

(2010) L. M. Staudt   Cold Spring Harbor Perspectives in Biology

Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells

(2009) T. Hideshima et al.   BLOOD

Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells

(2009) Hongjuan Dong et al.   LEUKEMIA & LYMPHOMA

Multiple myeloma

(2008) R. A. Kyle et al.   BLOOD

Molecular basis of bortezomib resistance: proteasome subunit  5 (PSMB5) gene mutation and overexpression of PSMB5 protein

(2008) R. Oerlemans et al.   BLOOD

Bone marrow microenvironment and the identification of new targets for myeloma therapy

(2008) K Podar et al.   LEUKEMIA

Bortezomib-Resistant Nuclear Factor- B Activity in Multiple Myeloma Cells

(2008) S. Markovina et al.   MOLECULAR CANCER RESEARCH